Details for Patent: 9,738,625

Try a free trial See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,738,625 protect, and when does it expire?

Patent 9,738,625 protects IDHIFA and is included in one NDA.

This patent has twenty-three patent family members in eighteen countries.

Summary for Patent: 9,738,625

Title:	Therapeutically active compounds and their methods of use
Abstract:	Provided are isocitrate dehydrogenase 2 (IDH2) inhibitor compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein. Also provided are polymorphic forms of the IDH2 inhibitor compounds characterized by X Ray powder diffraction patterns, having improved physicochemical properties that influence in vivo dissolution rate for formulation purposes.
Inventor(s):	Agresta; Samuel V. (Lexington, MA), Gu; Chong-Hui (Waban, MA), Schenkein; David (Boston, MA), Yang; Hua (Acton, MA), Guo; Liting (Suzhou, CN), Tang; Zhen (Suzhou, CN), Wang; Jianming (Suzhou, CN), Zhang; Yanfeng (Suzhou, CN), Zhou; Yan (Suzhou, CN)
Assignee:	Agios Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	14/909,451
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 9,738,625
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 9,738,625

Glossary

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-001	Aug 1, 2017		RX	Yes	No	➤ Sign Up	➤ Sign Up		Y			➤ Sign Up
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-002	Aug 1, 2017		RX	Yes	Yes	➤ Sign Up	➤ Sign Up		Y			➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 9,738,625

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	PCT/CN2013/081170	Aug 9, 2013

PCT Information
PCT Filed	August 01, 2014	PCT Application Number:	PCT/US2014/049469
PCT Publication Date:	February 05, 2015	PCT Publication Number:	WO2015/017821

International Family Members for US Patent 9,738,625

Subscribe to access the full database, or try a Free Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	097237	➤ Sign Up
Australia	2014295938	➤ Sign Up
Australia	2018247242	➤ Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.